1st Mar 2013 10:06
Epistem Holdings Plc
("Epistem" or "the Company")
Interim Results Date
Epistem Holdings Plc (LSE: EHP), the biotechnology and personalised medicine company will be announcing its unaudited interim results for the six months ended 31 December 2012 on Tuesday, 26 March 2013.
An analysts' meeting will be held at the offices of Peel Hunt LLP, Moor House, 120 London Wall, London EC2Y 5ET at 9.30 am.
Epistem Plc | ||
Matthew Walls | Chief Executive Officer | +44 (0) 161 606 7258 |
John Rylands | Finance Director | +44 (0) 161 606 7244 |
Peel Hunt LLP | ||
James Steel | +44 (0) 207 418 8900 | |
Vijay Barathan | +44 (0) 207 418 8900 | |
Cubitt Consulting Limited | ||
Mike Wort / Anna Dunphy | +44 (0) 20 7367 5100 |
Notes to Editors:
About Epistem
Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.
Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.
Related Shares:
Genedrive